Citations

Clear

4847 citation(s) found for "Tu, Eric".

The Global Evolution of Inflammatory Bowel Disease across Four Epidemiologic Stages
Hracs, Lindsay , Gorospe, Julia, Buie, Michael , Quan, Joshua , Goddard, Quinn , Caplan, Léa , Markovinović, Ante , Abbey, Yvonne , Abdullah, Murdani , Balderramo, Domingo , Bernstein, Çharles N. , Burisch, Johan , Chong, Vui Heng , Dotan, Iris , Ouali, Sara El , Forss, Anders, Dao, Hang Viet , Baños, Fabián Juliao , Kaibullayeva, Jamilya , Kobayashi, Taku , Miao, Yinglei , Ng, Ka Kei , Olén, Ola , Simadibrata, Marcellus , Sun, Yang , Turner, Dan , Vergara, Beatriz, Wei, Shu Chen, Yang, Suk‐Kyun , Kobayashi, Taku , Kaplan, Gilaad G. , Windsor, Joseph W. , Cummings, Michael K. , Coward, Stephanie B. , Williamson, Tyler S. , Abreu, María T. , Ahuja, Vineet , Ali, Raja Affendi Raja , Altuwaijri, Mansour A. , Banerjee, Rupa , Benchimol, Eric I. , Bernstein, Charles Noah , Brunet, Eduard , Dutta, Usha , Forbes, Angela J. , Forss, Anders, Gearry, Richard B. , Hartono, Juanda Leo , Hilmi, Ida Normiha , Hodges, Phoebe , Jones, Gareth‐Rhys , Kelly, Paul , Kotze, Paulo Gustavo , Lakatos, Péter L. , Lees, Charlie W. , Limsrivilai, Julajak , Lo, Bobby Zhao Sheng , Loftus, Edward V. , Ludvigsson, Jonas F. , Mak, Joyce Wing Yan , Okabayashi, Shinji , Panaccione, Remo , Paudel, Mukesh Sharma , Quaresma, Abel Botelho , Rubin, David T. , Suzuki, Hidekazu , Toro, Martín , Wei, Shu Chen, Yamamoto-Furusho, Jesus , Ng, Siew C.

Mayo Clinic

No container title available | January 23, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3846147/v1 Get It

Abstract During the 20th century, inflammatory bowel disease (IBD) was considered a disease of early-industrialized regions in North America, Europe, and Oceania. At the turn of the 21st century, incidence of IBD increased in newly-industrialized and emerging regions in Africa, Asia, and Latin America, while prevalence in early-industrialized regions started to grow steadily. Changes in incidence and prevalence denote evolution of IBD across four epidemiologic stages: Stage 1 (Emergence), characterized by low incidence and prevalence; stage 2 (Acceleration in Incidence), characterized by rapidly rising incidence and low prevalence; and stage 3 (Compounding Prevalence), characterized by decelerating, plateauing, or declining incidence and steadily rising prevalence. A fourth stage (Prevalence Equilibrium) has been proposed where the slope of prevalence plateaus due to shifting demographics of an aging IBD population, but it has not yet been evidenced. To date, these stages have been theoretical without specific incidence/prevalence indicators defining transition points. Using real-world data from 490 population-based studies comprising 80 global regions and spanning over a century (1920–2023), we show spatiotemporal transitions across stages 1–3 and model transition towards stage 4. Understanding the evolution of IBD across epidemiologic stages allows healthcare systems to better prepare for the future worldwide burden of IBD.
Small RNA Changes in Plasma Have Potential for Early Diagnosis of Alzheimer’s Disease before Symptom Onset
Palade, Joanna , Alsop, Eric , Courtright-Lim, Amanda , Keuren‐Jensen, Kendall Van , Palade, Joanna , Hsieh, Michael, Whitsett, Timothy G. , Galasko, Douglas

Mayo Clinic

Cells | January 23, 2024 | Volume: 13 | Issue: 3 | Pages: 207

10.3390/cells13030207 | PMID 38334599 Get It

Alzheimer’s disease (AD), due to its multifactorial nature and complex etiology, poses challenges for research, diagnosis, and treatment, and impacts millions worldwide. To address the need for minimally invasive, repeatable measures that aid in AD diagnosis and progression monitoring, studies leveraging RNAs associated with extracellular vesicles (EVs) in human biofluids have revealed AD-associated changes. However, the validation of AD biomarkers has suffered from the collection of samples from differing points in the disease time course or a lack of confirmed AD diagnoses. Here, we integrate clinical diagnosis and postmortem pathology data to form more accurate experimental groups and use small RNA sequencing to show that EVs from plasma can serve as a potential source of RNAs that reflect disease-related changes. Importantly, we demonstrated that these changes are identifiable in the EVs of preclinical patients, years before symptom manifestation, and that machine learning models based on differentially expressed RNAs can help predict disease conversion or progression. This research offers critical insight into early disease biomarkers and underscores the significance of accounting for disease progression and pathology in human AD studies.
Practice patterns and outcomes of endoscopic sleeve gastroplasty based on provider specialty
Gala, Khushboo, Brunaldi, Vitor , McGowan, Christopher , Sharaiha, Reem Z. , Maselli, Daniel B. , VanderWel, Brandon , Kedia, Prashant , Ujiki, Michael , Wilson, Erik B., Vargas, Eric J , Storm, Andrew C , Gala, Khushboo , Vargas, Eric J. , Storm, Andrew C. , Dayyeh, Barham K. Abu

Mayo Clinic

Endoscopy International Open | January 23, 2024 | Volume: 12 | Issue: 02 | Pages: E253-E261

10.1055/a-2251-3738 | PMID 38415023 Get It

Abstract Background and study aims Endoscopic sleeve gastroplasty (ESG) is performed in clinical practice by gastroenterologists and bariatric surgeons. Given the increasing regulatory approval and global adoption, we aimed to evaluate real-world outcomes in multidisciplinary practices involving bariatric surgeons and gastroenterologists across the United States. Patients and methods We included adult patients with obesity who underwent ESG from January 2013 to August 2022 in seven academic and private centers in the United States. Patient and procedure characteristics, serious adverse events (SAEs), and weight loss outcomes up to 24 months were analyzed. SPSS (version 29.0) was used for all statistical analyses. Results A total of 1506 patients from seven sites included 235 (15.6%) treated by surgeons and 1271 (84.4%) treated by gastroenterologists. There were no baseline differences between groups. Gastroenterologists used argon plasma coagulation for marking significantly more often than surgeons (P<0.001). Surgeons placed sutures in the fundus in all instances whereas gastroenterologist placed them in the fundus in less than 1% of the cases (P<0.001>). Procedure times were significantly different between groups, with surgeons requiring approximately 20 minutes more during the procedure than gastroenterologists (P<0.001). Percent total body weight loss (%TBWL) and percent responders achieving >10 and >15% TBWL were similar between the two groups at 12, 18, and 24 months. Rates of SAEs were low and similar at 1.7% for surgeons and 2.7% for gastroenterologists (P>0.05). Conclusions Data from a large US cohort show significant and sustained weight loss with ESG and an excellent safety profile in both bariatric surgery and gastroenterology practices, supporting the scalability of the procedure across practices in a multidisciplinary setting.
Alliance A022101: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation, ablation, and surgery (ERASur).
Gholami, Sepideh , White, Sarah B. , Goulet, Christopher C., Jee, Kyung‐Wook , Wright, Chadwick , Yaeger, Rona , Shergill, Ardaman , Hong, Theodore S. , Meyerhardt, Jeffrey A. , Meyerhardt, Jeffrey A , Hitchcock, Kathryn E. , Romesser, Paul B. , Shi, Qian , Dixon, Jesse G. , Wu, Christina , George, Thomas J. , O’Reilly, Eileen M. , Miller, Eric D.

Mayo Clinic

Journal of Clinical Oncology | January 22, 2024 | Volume: 42 | Issue: 3_suppl | Pages: TPS236-TPS236

10.1200/jco.2024.42.3_suppl.tps236 Get It

TPS236 Background: For patients with oligometastatic colorectal cancer (CRC), aggressive local therapy of isolated metastases, particularly in the liver, has been associated with long-term progression-free survival and overall survival (OS) primarily based on retrospective evidence. However, in patients with limited metastatic CRC that is deemed inoperable or those with additional disease outside of the liver or lungs, the role of local ablative therapies, including microwave ablation (MWA) and stereotactic body radiation therapy (SBRT), to render patients disease free is less clear. Further, despite the long history of treating oligometastatic CRC with local therapy, which is provider biased and not evidence based, questions remain regarding the benefit of extending the paradigm of metastatic directed therapy to patients with more extensive disease. This trial seeks to use a pragmatic multimodality approach that mirrors the current clinical dilemma. This study is designed to evaluate the safety and efficacy of adding total ablative therapy (TAT) of all sites of disease to standard of care systemic treatment in those with limited metastatic CRC. Methods: A022101 is a National Clinical Trials Network randomized phase III study planned to enroll 364 patients with newly diagnosed metastatic CRC (BRAF wild-type, microsatellite stable) with ≤4 sites of metastatic disease on baseline imaging. Liver-only metastatic disease is not permitted, and lesions must be amenable to any combination of surgical resection, MWA, and/or SBRT with SBRT required for at least one lesion. Patients receive first-line systemic therapy for 4-6 months and are then randomized 1:1, stratified by number of metastatic organ sites (1-2 vs. 3-4), timing of metastatic disease diagnosis (de novo vs. secondary), and presence of metastatic disease outside the liver and lungs in at least one site. Patients in Arm 1 will receive TAT which consists of treatment of all metastatic sites with SBRT ± MWA ± surgical resection followed by standard of care systemic therapy. Patients in Arm 2 will continue with standard of care systemic therapy alone. The primary endpoint is OS. Secondary endpoints include event-free survival, treatment-related toxicities, and local recurrence with exploratory biomarker analyses. The study needs 346 evaluable patients combined in the 2 arms to demonstrate an improvement in OS with a hazard ratio of 0.7 to provide 80% power with a one-sided alpha of 5%. The trial utilizes a group sequential design with two interim analyses (25% and 50% of events) for futility. The trial activated in January 2023 and recruitment is ongoing. Support: U10CA180821, U10CA180882; https://acknowledgments.alliancefound.org. U10CA180820 (ECOG-ACRIN); U10CA180868 (NRG); U10CA180888 (SWOG). Clinical trial information: NCT05673148 .
Kinetics of CA19-9 decline in a randomized phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracial/leucovorin (NALIRIFOX) or nab-paclitaxel plus gemcitabine (GEM+NABP) in patients who have not previously received chemotherapy for met
Chandana, Sreenivasa R , Pazo-Cid, Roberto , Dean, Andrew , Lee, Woo Jin , Goetze, Thorsten Oliver , Paulson, Andrew Scott , Pant, Shubham , Hubner, Richard , Xiao, Zhimin , Li, Jia , Benzaghou, Fawzi, Wainberg, Zev A. , Melisi, Davide , Macarulla, Teresa , Fouchardière, Christelle de la , Kišš, Igor , Cutsem, Eric Van , Bekaii‐Saab, Tanios , Pant, Shubham , O’Reilly, Eileen M.

Mayo Clinic

Journal of Clinical Oncology | January 22, 2024 | Volume: 42 | Issue: 3_suppl | Pages: 687-687

10.1200/jco.2024.42.3_suppl.687 Get It

687 Background: The NAPOLI 3 study (NCT04083235, N = 770) reported that NALIRIFOX improved overall survival (OS) vs Gem+NabP with manageable toxicity in 1L treatment of metastatic pancreatic adenocarcinoma. We explored changes in CA19-9 levels and their potential associations with efficacy as an important tumor marker in pancreatic adenocarcinoma. Methods: In NAPOLI 3, CA19-9 was evaluated at baseline and every 8 weeks until patients discontinued study treatment. The detection limit of CA19-9 was 8000 kU/L in this study. The Cox proportional hazards regression and logistic regression were employed to investigate the relationship between CA19-9 decrease and OS, progression-free survival (PFS), and overall response rate (ORR). Results: Patients with evaluable CA19-9 (levels =< 8000) at baseline and additional measurements at weeks 8 and 16 were included in the analysis (NALIRIFOX, n = 179; Gem+NabP, n = 194). The median baseline CA19-9 level was 378.0 and 409.7 kU/L for the NALIRIFOX and Gem+NabP arms, respectively. Overall, patients with (vs without) any CA 19-9 decrease by week 16 had a higher ORR (59.9% vs 35.2%; p = 0.002), a longer median PFS (9.2 vs 6.2 months; p < 0.001) and a longer median OS (14.2 vs 8.7 months; p = 0.005), respectively in a pooled analysis of the treatments. In the NALIRIFOX arm, patients with any CA19-9 decrease by week 16 had a higher confirmed ORR of 65.1% compared with those without at 42.4% ( p < 0.001), a median PFS of 9.5 vs 7.1 months ( p < 0.001) and a median OS of 15.4 versus 8.4 months ( p = 0.004), respectively. In the Gem+NabP arm, patients with CA19-9 decrease by week 16 had a higher ORR of 55.5% compared with those without at 23.8% ( p = 0.012), a median PFS of 7.6 versus 5.8 months ( p < 0.001) and a median OS of 13.7 versus 11.9 months ( p = 0.235), respectively. Conclusions: CA19-9 decrease by week 16 has the potential to be an early prognostic factor for OS, PFS and ORR. The results should be interpreted with caution as a considerable percentage of patients were excluded due to non-evaluable CA19-9 that exceeded the lab detection limit of 8000 kU/L. Clinical trial information: NCT04083235 .
Outcomes and Attributes Patients Value When Choosing Glucose-Lowering Medications: A Mixed-Methods Study
Bautista, Andrea E. Garcia, Umpierrez, Guillermo E. , Galindo, Rodolfo J. , Brito, Juan P. , Montori, Víctor M. , Gockerman, Janet P., Tesulov, Michael, Labatte, Bertina, Mickelson, Mindy M. , Golembiewski, Elizabeth H , Garcia Bautista, Andrea E, Umpierrez, Guillermo E. , Galindo, Rodolfo J , Montori, Victor M , McCoy, Rozalina Grubina , Brito, Juan P , Golembiewski, Elizabeth H. , Polley, Eric C. , Tesulov, Michael, Labatte, Bertina, Mickelson, Mindy M , McCoy, Rozalina G.

Mayo Clinic

Clinical Diabetes | January 22, 2024 | Volume: 42 | Issue: 3 | Pages: 371-387

10.2337/cd23-0042 | PMID 39015157 Get It

This mixed-methods study sought to identify pharmacotherapy preferences among 40 noninsulin-treated adults with type 2 diabetes receiving care at two U.S. health care systems. Participants ranked by relative importance various health outcomes and medication attributes and then contextualized their rankings. Most participants ranked blindness (63%), death (60%), heart attack (48%), and heart failure (48%) as the most important health outcomes and glucose-lowering efficacy (68%) as the most important medication attribute, followed by oral administration (45%) and lack of gastrointestinal side effects (38%).
Does the number of social factors affect long-term patient-reported outcomes and satisfaction in those with cervical myelopathy? A QOD study
Park, Christine , Shaffrey, Christopher I. , Than, Khoi D. , Bisson, Erica F. , Sherrod, Brandon A. , Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Shaffrey, Mark E., Buchholz, Avery L., Tumialán, Luis M. , Turner, Jay D. , Chan, Andrew K. , Chou, Dean , Chaudhry, Nauman S. , Haid, Regis W., Mummaneni, Praveen V. , Michalopoulos, Giorgos D. , Bydon, Mohamad , Gottfried, Oren N., Michalopoulos, Georgios D, Michalopoulos, Giorgos , Park, Paul , Agarwal, Nitin

Mayo Clinic

Journal of Neurosurgery: Spine | January 20, 2024 | Volume: 40 | Issue: 4 | Pages: 428-438

10.3171/2023.11.spine23127 | PMID 38241683 Get It

OBJECTIVE It is not clear whether there is an additive effect of social factors in keeping patients with cervical spondylotic myelopathy (CSM) from achieving both a minimum clinically important difference (MCID) in outcomes and satisfaction after surgery. The aim of this study was to explore the effect of multiple social factors on postoperative outcomes and satisfaction. METHODS This was a multiinstitutional, retrospective study of the prospective Quality Outcomes Database (QOD) CSM cohort, which included patients aged 18 years or older who were diagnosed with primary CSM and underwent operative management. Social factors included race (White vs non-White), education (high school or below vs above), employment (employed vs not), and insurance (private vs nonprivate). Patients were considered to have improved from surgery if the following criteria were met: 1) they reported a score of 1 or 2 on the North American Spine Society index, and 2) they met the MCID in patient-reported outcomes (i.e., visual analog scale [VAS] neck and arm pain, Neck Disability Index [NDI], and EuroQol-5D [EQ-5D]). RESULTS Of the 1141 patients included in the study, 205 (18.0%) had 0, 347 (30.4%) had 1, 334 (29.3%) had 2, and 255 (22.3%) had 3 social factors. The 24-month follow-up rate was > 80% for all patient-reported outcomes. After adjusting for all relevant covariates (p < 0.02), patients with 1 or more social factors were less likely to improve from surgery in all measured outcomes including VAS neck pain (OR 0.90, 95% CI 0.83–0.99) and arm pain (OR 0.88, 95% CI 0.80–0.96); NDI (OR 0.90, 95% CI 0.83–0.98); and EQ-5D (OR 0.90, 95% CI 0.83–0.97) (all p < 0.05) compared to those without any social factors. Patients with 2 social factors (outcomes: neck pain OR 0.86, arm pain OR 0.81, NDI OR 0.84, EQ-5D OR 0.81; all p < 0.05) or 3 social factors (outcomes: neck pain OR 0.84, arm pain OR 0.84, NDI OR 0.84, EQ-5D OR 0.84; all p < 0.05) were more likely to fare worse in all outcomes compared to those with only 1 social factor. CONCLUSIONS Compared to those without any social factors, patients who had at least 1 social factor were less likely to achieve MCID and feel satisfied after surgery. The effect of social factors is additive in that patients with a higher number of factors are less likely to improve compared to those with only 1 social factor.
Effect of 3-Dimensional, Virtual Reality Models for Surgical Planning of Robotic Partial Nephrectomy on Surgical Outcomes: Qualitative Data from a Randomized Clinical Trial
Shirk, Joseph D. , Thiel, David D. , Wallen, Eric, Linehan, Jennifer, White, Wesley M. , Badani, Ketan K. , Porter, James

Mayo Clinic

JU Open Plus | January 19, 2024 | Volume: 2 | Issue: 1 | Pages: No page available

10.1097/ju9.0000000000000101 Get It

Purpose: Planning for robotic-assisted partial nephrectomy requires surgeons to review two-dimensional CT or MRI scans to understand three-dimensional (3D) anatomy. We sought to determine the drivers of improvements in key surgical outcomes when using patient-specific 3D virtual reality (VR) models for operative planning. Materials and Methods: A multicenter, randomized, single-blind clinical trial was conducted from January 2019 to December 2020. Patients undergoing robotic-assisted partial nephrectomy were randomly assigned to a control group undergoing usual preoperative planning with CT and/or MRI only or to an intervention group where imaging was supplemented with a 3D VR model. A survey was administered to surgeons after review of the model and after the operation. The primary outcome measure was operative time, and secondary outcomes included clamp time, estimated blood loss, and hospital stay. Results: Qualitative data analysis of 44 cases in the treatment arm was performed. Surgeons reported seeing anatomic details much better in the 3D model 55% of the time and modified their preoperative plan based on anatomy shown in the 3D model 30% of the time. Cases in which the surgeon reported modifying their preoperative plan after viewing the model (30%) had significantly lower operative time, blood loss, and clamp time (P < .05). In addition, increased surgeon confidence after viewing the model significantly lowered operative time, estimated blood loss, and clamp time (P < .05). Conclusions: We demonstrate that surgeons who use 3D VR models for robotic kidney surgery are able to visualize anatomic structures and select the optimal approach, leading to better surgical outcomes. Trial Registration: ClinicalTrials.gov identifier NCT0333434.
Enhancing Patient Care in Rare Genetic Diseases: An HPO-based Phenotyping Pipeline
Xiao, Yao , Enayati, Moein , Schaeferle, Gavin M., Lanpher, Brendan C. , Klee, Eric W. , Ngufor, Che

Mayo Clinic

2023 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) | January 18, 2024 | Volume: No volume available | Issue: No issue available | Pages: 2754-2760

10.1109/bibm58861.2023.10385978 Get It

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination
Cynthia, X. , Sanati, Souzan , Leitch, A. Marilyn , Unzeitig, Gary, Fernández-Martínez, Aranzazu , Fan, Cheng , Gibbs, Richard A. , Dockter, Travis , Hahn, Olwen, Guenther, Joseph M., Caudle, Abigail S. , Crouch, Erika C., Tiersten, Amy , Mita, Monica , Razaq, Wajeeha, Rimawi, Mothaffar F. , Weiss, Anna , Perou, Charles M. , Carey, Lisa A. , Dockter, Travis J, Carey, Lisa A , Perou, Charles M , Rimawi, Mothaffar , Fernandez-Martinez, Aranzazu , Suman, Vera J. , Vij, Kiran R , Anurag, Meenakshi , Hoog, Jeremy , Watson, Mark A. , Hieken, Tina J. , Wang, Yang , Winer, Eric P. , Hunt, Kelly K. , Ellis, Matthew J. , Partridge, Ann H.

Mayo Clinic

JAMA Oncology | January 18, 2024 | Volume: 10 | Issue: 3 | Pages: 362

10.1001/jamaoncol.2023.6038 | PMID 38236590 Get It

Importance Adding fulvestrant to anastrozole (A+F) improved survival in postmenopausal women with advanced estrogen receptor (ER)–positive/ERBB2 (formerly HER2)–negative breast cancer. However, the combination has not been tested in early-stage disease. Objective To determine whether neoadjuvant fulvestrant or A+F increases the rate of pathologic complete response or ypT1-2N0/N1mic/Ki67 2.7% or less residual disease (referred to as endocrine-sensitive disease) over anastrozole alone. Design, Setting, and Participants A phase 3 randomized clinical trial assessing differences in clinical and correlative outcomes between each of the fulvestrant-containing arms and the anastrozole arm. Postmenopausal women with clinical stage II to III, ER-rich (Allred score 6-8 or &amp;gt;66%)/ERBB2-negative breast cancer were included. All analyses were based on data frozen on March 2, 2023. Interventions Patients received anastrozole, fulvestrant, or a combination for 6 months preoperatively. Tumor Ki67 was assessed at week 4 and optionally at week 12, and if greater than 10% at either time point, the patient switched to neoadjuvant chemotherapy or immediate surgery. Main Outcomes and Measures The primary outcome was the endocrine-sensitive disease rate (ESDR). A secondary outcome was the percentage change in Ki67 after 4 weeks of neoadjuvant endocrine therapy (NET) (week 4 Ki67 suppression). Results Between February 2014 and November 2018, 1362 female patients (mean [SD] age, 65.0 [8.2] years) were enrolled. Among the 1298 evaluable patients, ESDRs were 18.7% (95% CI, 15.1%-22.7%), 22.8% (95% CI, 18.9%-27.1%), and 20.5% (95% CI, 16.8%-24.6%) with anastrozole, fulvestrant, and A+F, respectively. Compared to anastrozole, neither fulvestrant-containing regimen significantly improved ESDR or week 4 Ki67 suppression. The rate of week 4 or week 12 Ki67 greater than 10% was 25.1%, 24.2%, and 15.7% with anastrozole, fulvestrant, and A+F, respectively. Pathologic complete response/residual cancer burden class I occurred in 8 of 167 patients and 17 of 167 patients, respectively (15.0%; 95% CI, 9.9%-21.3%), after switching to neoadjuvant chemotherapy due to week 4 or week 12 Ki67 greater than 10%. PAM50 subtyping derived from RNA sequencing of baseline biopsies available for 753 patients (58%) identified 394 luminal A, 304 luminal B, and 55 nonluminal tumors. A+F led to a greater week 4 Ki67 suppression than anastrozole alone in luminal B tumors (median [IQR], −90.4% [−95.2 to −81.9%] vs −76.7% [−89.0 to −55.6%]; P &amp;lt; .001), but not luminal A tumors. Thirty-six nonluminal tumors (65.5%) had a week 4 or week 12 Ki67 greater than 10%. Conclusions and Relevance In this randomized clinical trial, neither fulvestrant nor A+F significantly improved the 6-month ESDR over anastrozole in ER-rich/ERBB2-negative breast cancer. Aromatase inhibition remains the standard-of-care NET. Differential NET response by PAM50 subtype in exploratory analyses warrants further investigation. Trial Registration ClinicalTrials.gov Identifier: NCT01953588